Trial Profile
Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms MAP3BSS
- 26 Mar 2024 Status changed from active, no longer recruiting to completed.
- 23 Dec 2014 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019 as reported by ClinicalTrials.gov record.
- 09 Jul 2013 Planned end date changed from 1 Jun 2015 to 1 Jun 2017 as reported by ClinicalTrials.gov.